The cancer-testis antigen, sperm protein 17, a new biomarker and immunological target in head and neck squamous cell carcinoma

Schutt, Christopher A.; Mirandola, Leonardo; Figueroa, José A.; Nguyen, Diane; Cordero, Joehassin; Bumm, Klauss; Judson, Benjamin L.; Chiriva‐Internati, Maurizio

doi:10.18632/oncotarget.22213

Cited by 10 publications

(7 citation statements)

References 27 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in the last decade, several specific genetic targets have been identified that allow for targeted immunotherapeutic approaches [ 22 ]. This search for specific biomarkers has led to the identification of circulating antibodies specifically recognizing the cancer-testis antigen SP17, which was found to be present in 31% of serum samples taken from patients and not present in serum from the healthy control group [ 23 ]. The authors compared it to previously reported anti-p53 auto-antibodies, which were found in only 25% of HNC patients [ 24 ].…”

Section: Cancer Auto-antibodiesmentioning

confidence: 99%

Anti-Cancer Auto-Antibodies: Roles, Applications and Open Issues

Jonge

Iamele

Maggi

et al. 2021

Cancers

View full text Add to dashboard Cite

Auto-antibodies are classically associated with autoimmune diseases, where they are an integral part of diagnostic panels. However, recent evidence is accumulating on the presence of auto-antibodies against single or selected panels of auto-antigens in many types of cancer. Auto-antibodies might initially represent an epiphenomenon derived from the inflammatory environment induced by the tumor. However, their effect on tumor evolution can be crucial, as is discussed in this paper. It has been demonstrated that some of these auto-antibodies can be used for early detection and cancer staging, as well as for monitoring of cancer regression during treatment and follow up. Interestingly, certain auto-antibodies were found to promote cancer progression and metastasis, while others contribute to the body’s defense against it. Moreover, auto-antibodies are of a polyclonal nature, which means that often several antibodies are involved in the response to a single tumor antigen. Dissection of these antibody specificities is now possible, allowing their identification at the genetic, structural, and epitope levels. In this review, we report the evidence available on the presence of auto-antibodies in the main cancer types and discuss some of the open issues that still need to be addressed by the research community.

show abstract

Section: Cancer Auto-antibodiesmentioning

confidence: 99%

Anti-Cancer Auto-Antibodies: Roles, Applications and Open Issues

Jonge

Iamele

Maggi

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Cancer/testis antigens (CTAs) are expressed in various cancers, rendering them ideal targets for immunotherapy [ 191 ]. Compared with conventional targets such as EGFR, HER2, VEGF and mucin 1 (MUC1), which are also expressed in normal tissues, CTAs hold great potential for minimizing off‐tumor toxicity [ 192 ].…”

Section: Scfv and Nanobodies In Car‐t/nk Cellsmentioning

confidence: 99%

Antibody variable region engineering for improving cancer immunotherapy

Lou

Cao

2022

Cancer Communications

View full text Add to dashboard Cite

The efficacy and specificity of conventional monoclonal antibody (mAb) drugs in the clinic require further improvement. Currently, the development and application of novel antibody formats for improving cancer immunotherapy have attracted much attention. Variable region‐retaining antibody fragments, such as antigen‐binding fragment (Fab), single‐chain variable fragment (scFv), bispecific antibody, and bi/trispecific cell engagers, are engineered with humanization, multivalent antibody construction, affinity optimization and antibody masking for targeting tumor cells and killer cells to improve antibody‐based therapy potency, efficacy and specificity. In this review, we summarize the application of antibody variable region engineering and discuss the future direction of antibody engineering for improving cancer therapies.

show abstract

“…The SP17 protein was also found in HNSCC patients. This suggests that it is a promising immunotherapeutic target, as well as a possible disease biomarker for HNSCC (Schutt et al 2017 ). These findings indicate that peptide-based vaccine is a promising treatment for advanced HNSCC.…”

Section: Peptide Vaccines For Hnscc Patientsmentioning

confidence: 99%

Head and Neck Squamous Cell Carcinoma: Risk Factors, Molecular Alterations, Immunology and Peptide Vaccines

Sun

Chen

et al. 2021

Int J Pept Res Ther

View full text Add to dashboard Cite

Head and neck squamous cell carcinoma (HNSCC) arises from the epithelial lining of the oral cavity, hypopharynx, oropharynx, and larynx. There are several potential risk factors that cause the generation of HNSCC, including cigarette smoking, alcohol consumption, betel quid chewing, inadequate nutrition, poor oral hygiene, HPV and Epstein–Barr virus, and Candida albicans infections. HNSCC has causative links to both environmental factors and genetic mutations, with the latter playing a more critical role in cancer progression. These molecular changes to epithelial cells include the inactivation of cancer suppressor genes and proto-oncogenes overexpression, resulting in tumour cell proliferation and distant metastasis. HNSCC patients have impaired dendritic cell (DC) and natural killer (NK) cell functions, increased production of higher immune-suppressive molecules, loss of regulatory T cells and co-stimulatory molecules and major histocompatibility complex (MHC) class Ι molecules, lower number of lymphocyte subsets, and a poor response to antigen-presenting cells. At present, the standard treatment modalities for HNSCC patients include surgery, chemotherapy and radiotherapy, and combinatorial therapy. Despite advances in the development of novel treatment modalities over the last few decades, survival rates of HNSCC patients have not increased. To establish effective immunotherapies, a greater understanding of interactions between the immune system and HNSCC is required, and there is a particular need to develop novel therapeutic options. A therapeutic cancer vaccine has been proposed as a promising method to improve outcome by inducing a powerful adaptive immune response that leads to cancer cell elimination. Compared with other vaccines, peptide cancer vaccines are more robust and specific. In the past few years, there have been remarkable achievements in peptide-based vaccines for HNSCC patients. Here, we summarize the latest molecular alterations in HNSCC, explore the immune response to HNSCC, and discuss the latest developments in peptide-based cancer vaccine strategies. This review highlights areas for valuable future research focusing on peptide-based cancer vaccines.

show abstract

The cancer-testis antigen, sperm protein 17, a new biomarker and immunological target in head and neck squamous cell carcinoma

Cited by 10 publications

References 27 publications

Anti-Cancer Auto-Antibodies: Roles, Applications and Open Issues

Anti-Cancer Auto-Antibodies: Roles, Applications and Open Issues

Antibody variable region engineering for improving cancer immunotherapy

Head and Neck Squamous Cell Carcinoma: Risk Factors, Molecular Alterations, Immunology and Peptide Vaccines

Contact Info

Product

Resources

About